Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  PI3K alpha inhibitor MLN1117
Find trials that include:  Any drugs shown
Results 1-5 of 5 for your search:
Start Over
Docetaxel With or Without MLN1117 in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MLN1117-1501, NCI-2015-00520, 2014-004281-25, NCT02393209
MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: C31005, NCI-2016-00540, U1111-1172-1808, 2015-002133-22, NCT02724020
Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: C31004, NCI-2016-00972, 2014-005394-37, U1111-1168-1824, NCT02725268
Phase 1b Study of MLN0128 in Combination With MLN1117 in Adult Patients With Advanced Nonhematologic Malignancies
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C32001, NCI-2014-01567, 2013-000466-11, NCT01899053
MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: C032-6001 (MLN1117-1003), NCI-2015-02103, 2015-001032-38, REec-2016-2039, MLN1117-1003, UTN, NCT02551055
Start Over